Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €76.50 ($88.95) target price by stock analysts at Sanford C. Bernstein in a report released on Friday. The firm presently has a “buy” rating on the stock. Sanford C. Bernstein’s price objective would indicate a potential upside of 96.20% from the stock’s current price.
Several other research firms also recently commented on FRE. HSBC set a €74.00 ($86.05) price objective on Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Monday, September 3rd. Kepler Capital Markets set a €65.00 ($75.58) price objective on Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Tuesday, November 20th. Berenberg Bank set a €81.85 ($95.17) price objective on Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Friday, November 23rd. DZ Bank reissued a “neutral” rating on shares of Fresenius SE & Co KGaA in a report on Tuesday, October 2nd. Finally, Goldman Sachs Group set a €66.00 ($76.74) price objective on Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Monday, October 1st. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of €68.69 ($79.88).
Shares of FRA FRE traded down €8.39 ($9.76) during trading hours on Friday, hitting €38.99 ($45.34). The company had a trading volume of 10,445,184 shares. Fresenius SE & Co KGaA has a 1-year low of €60.16 ($69.95) and a 1-year high of €80.00 ($93.02).
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.
Recommended Story: Moving Average (MA)
Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.